




Product datasheet

Anti-LRP5 antibody ab204901

4 Images

Overview

Product name	Anti-LRP5 antibody
Description	Rabbit polyclonal to LRP5
Host species	Rabbit
Tested applications	Suitable for: IHC-P
Species reactivity	Reacts with: Human Predicted to work with: Mouse 
Immunogen	Recombinant fragment corresponding to Human LRP5 aa 1410-1533. Sequence: VVCQRYAGANGPFPHEYVSGTPHVPLNFIAPGGSQHGPF TGACGKSMMS SVSLMGGRGGVPLYDRNHVTGASSSSSSSTKATLYPPILN PPPSPATD PSLYNMDMFYSSNIPATARPYRPII Database link: O75197  Run BLAST with  Run BLAST with
Positive control	IHC-P: Human liver, small intestine and kidney tissue.
General notes	<p>Reproducibility is key to advancing scientific discovery and accelerating scientists' next breakthrough.</p> <p>Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.</p> <p>We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.</p> <p>In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.</p> <p>We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.</p> <p>Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.</p> <p>Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team</p>

ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.

Properties

Form	Liquid
Storage instructions	Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage buffer	pH: 7.20 Preservative: 0.02% Sodium azide Constituents: 40% Glycerol (glycerin, glycerine), 59% PBS
Purity	Immunogen affinity purified
Clonality	Polyclonal
Isotype	IgG

Applications

Our [Abpromise guarantee](#) covers the use of **ab204901** in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application	Abreviews	Notes
IHC-P		1/50 - 1/200. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

Target

Function	Component of the Wnt-Fzd-LRP5-LRP6 complex that triggers beta-catenin signaling through inducing aggregation of receptor-ligand complexes into ribosome-sized signalsomes. Cell-surface coreceptor of Wnt/beta-catenin signaling, which plays a pivotal role in bone formation. The Wnt-induced Fzd/LRP6 coreceptor complex recruits DVL1 polymers to the plasma membrane which, in turn, recruits the AXIN1/GSK3B-complex to the cell surface promoting the formation of signalsomes and inhibiting AXIN1/GSK3-mediated phosphorylation and destruction of beta-catenin. Appears to be required for postnatal control of vascular regression in the eye. Required for posterior patterning of the epiblast during gastrulation.
Tissue specificity	Widely expressed, with the highest level of expression in the liver.
Involvement in disease	Defects in LRP5 are the cause of vitreoretinopathy exudative type 4 (EVR4) [MIM:601813]. EVR4 is a disorder of the retinal vasculature characterized by an abrupt cessation of growth of peripheral capillaries, leading to an avascular peripheral retina. This may lead to compensatory retinal neovascularization, which is thought to be induced by hypoxia from the initial avascular insult. New vessels are prone to leakage and rupture causing exudates and bleeding, followed by scarring, retinal detachment and blindness. Clinical features can be highly variable, even within the same family. Patients with mild forms of the disease are asymptomatic, and their only disease related abnormality is an arc of avascular retina in the extreme temporal periphery. EVR4 inheritance can be autosomal dominant or recessive.

Genetic variations in LRP5 are a cause of susceptibility to osteoporosis (OSTEOP) [MIM:166710]; also known as senile osteoporosis or postmenopausal osteoporosis. Osteoporosis is characterized by reduced bone mass, disruption of bone microarchitecture without alteration in the composition of bone. Osteoporotic bones are more at risk of fracture. Defects in LRP5 are the cause of osteoporosis-pseudoglioma syndrome (OPPG) [MIM:259770]; also known as osteogenesis imperfecta ocular form. OPPG is a recessive disorder characterized by very low bone mass and blindness. Individuals with OPPG are prone to develop bone fractures and deformations and have various eye abnormalities, including phthisis bulbi, retinal detachments, falciform folds or persistent vitreal vasculature.

Defects in LRP5 are a cause of high bone mass trait (HBM) [MIM:601884]. HBM is a rare phenotype characterized by exceptionally dense bones. HBM individuals show otherwise a completely normal skeletal structure and no other unusual clinical findings.

Defects in LRP5 are a cause of endosteal hyperostosis Worth type (WENHY) [MIM:144750]; also known as autosomal dominant osteosclerosis. WENHY is an autosomal dominant sclerosing bone dysplasia clinically characterized by elongation of the mandible, increased gonial angle, flattened forehead, and the presence of a slowly enlarging osseous prominence of the hard palate (torus palatinus). Serum calcium, phosphorus and alkaline phosphatase levels are normal. Radiologically, it is characterized by early thickening of the endosteum of long bones, the skull and of the mandible. With advancing age, the trabeculae of the metaphysis become thickened. WENHY becomes clinically and radiologically evident by adolescence, does not cause deformity except in the skull and mandible, and is not associated with bone pain or fracture. Affected patients have normal height, proportion, intelligence and longevity.

Defects in LRP5 are the cause of osteopetrosis autosomal dominant type 1 (OPTA1) [MIM:607634]. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. OPTA1 is characterized by generalized osteosclerosis most pronounced in the cranial vault. Patients are often asymptomatic, but some suffer from pain and hearing loss. It appears to be the only type of osteopetrosis not associated with an increased fracture rate.

Defects in LRP5 are the cause of van Buchem disease type 2 (VBCH2)[MIM:607636]. VBCH2 is an autosomal dominant sclerosing bone dysplasia characterized by cranial osteosclerosis, thickened calvaria and cortices of long bones, enlarged mandible and normal serum alkaline phosphatase levels.

Sequence similarities

Belongs to the LDLR family.
 Contains 4 EGF-like domains.
 Contains 3 LDL-receptor class A domains.
 Contains 20 LDL-receptor class B repeats.


Post-translational modifications

Phosphorylation of cytoplasmic PPPSP motifs regulates the signal transduction of the Wnt signaling pathway through acting as a docking site for AXIN1.

Cellular localization

Membrane. Endoplasmic reticulum. Chaperoned to the plasma membrane by MESD.


Images



Immunohistochemical analysis of human liver tissue labeling LRP5 in the cytoplasm of hepatocytes with ab204901 at a 1/50 dilution.

Performed heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.


Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-LRP5 antibody (ab204901)



Immunohistochemical analysis of human small intestine tissue labeling LRP5 in the cytoplasm of glandular cells with ab204901 at a 1/50 dilution.

Performed heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.


Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-LRP5 antibody (ab204901)



Immunohistochemical analysis of human kidney tissue labeling LRP5 in the cytoplasm of cells in tubules with ab204901 at a 1/50 dilution.

Performed heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-LRP5 antibody (ab204901)



Immunohistochemical analysis of human cerebellum tissue labeling LRP5 with ab204901 at a 1/50 dilution. No positivity as expected.

Performed heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-LRP5 antibody (ab204901)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

Our Abpromise to you: Quality guaranteed and expert technical support

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours

- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit <https://www.abcam.com/abpromise> or contact our technical team.

Terms and conditions

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors